Related Experiment Video
Updated: Jun 2, 2026
13:21
Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
Published on: July 21, 2011
Biocompatible blood pool MRI contrast agents based on hyaluronan
1JHU ICMIC Program, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Contrast Media & Molecular Imaging
|April 20, 2011
Summary
New biocompatible gadolinium contrast agents using hyaluronan show promise for magnetic resonance angiography. These agents enhance blood vessels for extended periods, with potential for clinical use.
Area of Science:
- Biomaterials Science
- Medical Imaging
- Polymer Chemistry
Background:
- Hyaluronan is a natural biopolymer and a key component of the extracellular matrix.
- Gadolinium-based contrast agents are widely used in magnetic resonance imaging (MRI).
- Developing safe and effective blood pool contrast agents is crucial for advanced angiography.
Purpose of the Study:
- To investigate biocompatible gadolinium blood pool contrast agents based on hyaluronan for magnetic resonance angiography (MRA).
- To synthesize and characterize gadolinium contrast agents using different molecular weights of hyaluronan.
- To evaluate the performance and biodistribution of these novel agents in MRA applications.
Main Methods:
- Synthesis of two gadolinium contrast agents using 16 kDa and 74 kDa hyaluronan.
- Characterization of relaxivity (R1) at 9.4 T and 25°C.
- In vivo evaluation of vascular enhancement and biodistribution over time.
Main Results:
- Synthesized hyaluronan-based gadolinium agents exhibited R1 relaxivity around 5 mM⁻¹s⁻¹ per gadolinium.
- Significant and prolonged enhancement of vasculature was observed.
- Initial excretion via the renal system, followed by uptake in the gastrointestinal tract.
Conclusions:
- Biocompatible hyaluronan-based gadolinium agents are effective for MRA.
- These agents demonstrate prolonged vascular enhancement and favorable biodistribution.
- High clinical translation potential exists due to hyaluronan's FDA approval and biocompatibility.
